Literature DB >> 19276352

Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray.

Mikiko Takikita1, Sean Altekruse, Charles F Lynch, Mark T Goodman, Brenda Y Hernandez, Mark Green, Wendy Cozen, Myles Cockburn, Maria Sibug Saber, Marie Topor, Chris Zeruto, Behnoush Abedi-Ardekani, Marsha E Reichman, Stephen M Hewitt.   

Abstract

Pancreatic cancer is the fourth leading cause of cancer death in the United States. Prognostic biomarkers are lacking, and treatment has limited effect on survival. Tissues from Surveillance, Epidemiology, and End Results registries (Iowa, Hawaii, and Los Angeles) were used to build a tissue microarray of 161 pancreatic tumors (113 resections and 48 biopsies). Proportional hazard models adjusted for age, race, sex, stage, time-period of diagnosis, and treatment. Associations were examined between markers (MUC1, MUC2, MUC5AC, synaptophysin, chromogranin, neuron specific enolase, epidermal growth factor receptor, HER2, CD5, CD138, CK5/6, CK19, CK20, and p53) and survival time from diagnosis. After adjusting for covariates, borderline statistically significant associations were seen between expression of each of the three mucins (MUC1, MUC2, and MUC5AC) and shorter survival time. The associations strengthened for 154 (96%) adenocarcinomas, particularly the 120 (75%) well-differentiated to moderately differentiated ductal adenocarcinomas, a tumor type that occurred more often in the cohort among White cases than cases of other racial origin (P<0.01). For differentiated ductal adenocarcinomas, associations with shorter survival time were seen for expression of all three mucins combined versus other mucin expression patterns (adjusted hazard ratio, 1.8; 95% confidence interval, 1.2-2.6) and for MUC2(+) versus MUC2(-) expression (adjusted hazard ratio, 1.6; 95% confidence interval, 1.1-2.4). Mucin gene expression, particularly MUC2 expression, may have prognostic value for differentiated adenocarcinomas. Tumor histologies differed in this and Japanese cohorts. The tissue microarray is available to evaluate other biomarkers. Tissue-based surveillance can be used to monitor tumor histology in populations and facilitate applied research.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276352      PMCID: PMC2711977          DOI: 10.1158/0008-5472.CAN-08-3879

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy.

Authors:  Akiko Nakamura; Michiko Horinouchi; Masamichi Goto; Kohji Nagata; Koro Sakoda; Sonshin Takao; Kohzoh Imai; Young S Kim; Eiichi Sato; Suguru Yonezawa
Journal:  J Pathol       Date:  2002-06       Impact factor: 7.996

2.  Expression of MUC apomucins in normal pancreas and pancreatic tumours.

Authors:  T Terada; T Ohta; M Sasaki; Y Nakanuma; Y S Kim
Journal:  J Pathol       Date:  1996-10       Impact factor: 7.996

3.  Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients.

Authors:  T Utsunomiya; S Yonezawa; H Sakamoto; H Kitamura; S Hokita; T Aiko; S Tanaka; T Irimura; Y S Kim; E Sato
Journal:  Clin Cancer Res       Date:  1998-11       Impact factor: 12.531

Review 4.  Molecular prognostic factors in patients with pancreatic cancer.

Authors:  Giuseppe Tonini; Francesco Pantano; Bruno Vincenzi; Armando Gabbrielli; Roberto Coppola; Daniele Santini
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

5.  Mucin gene expression in ovarian cancers.

Authors:  R L Giuntoli; G C Rodriguez; R S Whitaker; R Dodge; J A Voynow
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

6.  Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors.

Authors:  M Osako; S Yonezawa; B Siddiki; J Huang; J J Ho; Y S Kim; E Sato
Journal:  Cancer       Date:  1993-04-01       Impact factor: 6.860

7.  The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms.

Authors:  Suguru Yonezawa; Akiko Nakamura; Michiko Horinouchi; Eiichi Sato
Journal:  J Hepatobiliary Pancreat Surg       Date:  2002

Review 8.  Precursor lesions of pancreatic cancer: molecular pathology and clinical implications.

Authors:  Mansher Singh; Anirban Maitra
Journal:  Pancreatology       Date:  2007-04-18       Impact factor: 3.996

9.  Tissue microarrays for high-throughput molecular profiling of tumor specimens.

Authors:  J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

10.  Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives.

Authors:  David K Espey; Xiao-Cheng Wu; Judith Swan; Charles Wiggins; Melissa A Jim; Elizabeth Ward; Phyllis A Wingo; Holly L Howe; Lynn A G Ries; Barry A Miller; Ahmedin Jemal; Faruque Ahmed; Nathaniel Cobb; Judith S Kaur; Brenda K Edwards
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

View more
  37 in total

1.  Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma.

Authors:  Sabrina C Sopha; Purva Gopal; Nipun B Merchant; Frank L Revetta; David V Gold; Kay Washington; Chanjuan Shi
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

2.  Loss of SOD3 (EcSOD) Expression Promotes an Aggressive Phenotype in Human Pancreatic Ductal Adenocarcinoma.

Authors:  Brianne R O'Leary; Melissa A Fath; Andrew M Bellizzi; Jennifer E Hrabe; Anna M Button; Bryan G Allen; Adam J Case; Sean Altekruse; Brett A Wagner; Garry R Buettner; Charles F Lynch; Brenda Y Hernandez; Wendy Cozen; Robert A Beardsley; Jeffery Keene; Michael D Henry; Frederick E Domann; Douglas R Spitz; James J Mezhir
Journal:  Clin Cancer Res       Date:  2015-01-29       Impact factor: 12.531

Review 3.  Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer.

Authors:  Muzafar A Macha; Shiv Ram Krishn; Rahat Jahan; Kasturi Banerjee; Surinder K Batra; Maneesh Jain
Journal:  Cancer Treat Rev       Date:  2015-01-14       Impact factor: 12.111

4.  Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma.

Authors:  Amit Mahipal; Mary J Mcdonald; Agnieszka Witkiewicz; Brian I Carr
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

5.  Tissue microarrays as a tool in the discovery and validation of predictive biomarkers.

Authors:  Stephen M Hewitt
Journal:  Methods Mol Biol       Date:  2012

Review 6.  Mucins in pancreatic cancer and its microenvironment.

Authors:  Sukhwinder Kaur; Sushil Kumar; Navneet Momi; Aaron R Sasson; Surinder K Batra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-16       Impact factor: 46.802

7.  The sole presence of CDK4 is not a solid criterion for discriminating between tumor and healthy pancreatic tissues.

Authors:  Jordi Altirriba; Ainhoa García; Begoña Sánchez; Laura Haba; Sean Altekruse; Thomas Stratmann; Josep Antoni Bombí; Cristóbal Mezquita; Ramon Gomis; Conchi Mora
Journal:  Int J Cancer       Date:  2011-08-29       Impact factor: 7.396

8.  RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells.

Authors:  Sadaaki Yamazoe; Hiroaki Tanaka; Tetsuji Sawada; Ryosuke Amano; Nobuya Yamada; Masaichi Ohira; Kosei Hirakawa
Journal:  J Exp Clin Cancer Res       Date:  2010-05-23

Review 9.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

10.  Epstein-Barr virus patterns in US Burkitt lymphoma tumors from the SEER residual tissue repository during 1979-2009.

Authors:  Sam M Mbulaiteye; Sheeja T Pullarkat; Bharat N Nathwani; Lawrence M Weiss; Nagesh Rao; Benjamin Emmanuel; Charles F Lynch; Brenda Hernandez; Vishala Neppalli; Debra Hawes; Myles G Cockburn; Andre Kim; Makeda Williams; Sean Altekruse; Kishor Bhatia; Marc T Goodman; Wendy Cozen
Journal:  APMIS       Date:  2013-04-23       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.